MARINUS PHARMACEUTICALS INC (MRNS)

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 151 full-time employees. The company went IPO on 2014-07-31. The firm is focused on the development of therapeutics for seizure disorders. The Company’s commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The firm's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. Its ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Company Info

MARINUS PHARMACEUTICALS INC

Three Radnor Corporate Center, 100 Matsonford Rd, Suite 304

Radnor PENNSYLVANIA 19087

P: 14848014670

CEO: Scott Braunstein

Employees: 151

Website: https://marinuspharma.com/